RecruitingPHASE1, PHASE2NCT06292780
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Studying AL amyloidosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Regeneron Pharmaceuticals
- Principal Investigator
- Clinical Trial ManagementRegeneron Pharmaceuticals
- Intervention
- Linvoseltamab(drug)
- Enrollment
- 220 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2035
Study locations (18)
- City of Hope, Duarte, California, United States
- Colorado Blood Cancer Institute/SCRI, Denver, Colorado, United States
- Karmanos Cancer Institute, Detroit, Michigan, United States
- Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
- Ohio State University, Columbus, Ohio, United States
- SCRI Oncology Partners, Nashville, Tennessee, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- Seoul National University Hospital, Seoul, South Korea
- Asan Medical Center, Seoul, South Korea
- Samsung Medical Center, Seoul, South Korea
- Seoul St. Mary's Hospital - The Catholic University of Korea, Seoul, South Korea
- Hospital Universitari Son Espases, Palma, Balearic Islands, Spain
- Clinica Universidad de Navarra - Pamplona, Pamplona, Navarre, Spain
- Hospital de Cabuenes, Gijón, Principality of Asturias, Spain
- Universität de Barcelona- Institut d' Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- +3 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06292780 on ClinicalTrials.govOther trials for AL amyloidosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06963216A Study Investigating Coagadex in the Treatment AFXD Associated With AL AmyloidosisKedrion S.p.A.
- RECRUITINGPHASE3NCT07388602A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)Sinocelltech Ltd.
- RECRUITINGPHASE1, PHASE2NCT07266116Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis PatientsShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- RECRUITINGNCT07448935One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMSFondazione IRCCS Policlinico San Matteo di Pavia
- RECRUITINGNCT07448779Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and TreatmentFondazione IRCCS Policlinico San Matteo di Pavia
- RECRUITINGPHASE2NCT07110844Teclistamab-Daratumumab in AL AmyloidosisSuzanne Lentzsch, MD
- RECRUITINGPHASE1NCT07250269Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL AmyloidosisGracell Biotechnologies (Shanghai) Co., Ltd.
- RECRUITINGNCT07172243BE.Amycon Biobank & Data Registry UZ LeuvenUniversitaire Ziekenhuizen KU Leuven